Alnylam Pharmaceuticals, Inc.
ALNY
$332.92
$1.680.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 313.75M | 43.57M | -319.09M | -269.70M | -278.16M |
| Total Depreciation and Amortization | 55.66M | 56.32M | 56.50M | 57.56M | 56.67M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 599.46M | 645.90M | 481.29M | 489.70M | 427.26M |
| Change in Net Operating Assets | -444.78M | -479.92M | -234.24M | -322.67M | -214.08M |
| Cash from Operations | 524.08M | 265.86M | -15.54M | -45.11M | -8.31M |
| Capital Expenditure | -58.70M | -44.50M | -36.55M | -30.27M | -34.28M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 495.03M | 465.08M | -74.22M | 94.82M | -82.56M |
| Cash from Investing | 436.33M | 420.59M | -110.77M | 64.55M | -116.84M |
| Total Debt Issued | 645.69M | 646.37M | -- | -- | -- |
| Total Debt Repaid | -1.19B | -1.14B | -- | -- | -- |
| Issuance of Common Stock | 250.03M | 244.61M | 274.90M | 326.46M | 302.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8.27M | -70.10M | -43.31M | -17.13M | -8.79M |
| Cash from Financing | -305.19M | -319.51M | 231.59M | 309.33M | 294.16M |
| Foreign Exchange rate Adjustments | 34.94M | 23.37M | 39.39M | 8.76M | -15.24M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 690.16M | 390.30M | 144.67M | 337.53M | 153.77M |